Breast and Cervical Cancer Screening in a Semi-Urban African Setting: Evidence from Franceville, Gabon (2015–2021) - Takeaways - MDSpire

Breast and Cervical Cancer Screening in a Semi-Urban African Setting: Evidence from Franceville, Gabon (2015–2021)

  • By

  • MOUSSAVOU-BOUNDZANGA, Pamela

  • Togola, Moussa

  • Bivigou-Mboumba, Berthold

  • Ambounda, Nathalie Ledaga

  • MOUINGA ONDEME, Augustin

  • Mfouo-Tynga, Ivan

  • Mavoungou-Niongo, Anne-Danielle

  • Nzingou, Aime Roger

  • Mombo, Landry Erik

  • Bisseye, Cyrille

  • Pineau, Pascal

  • April 28, 2026

  • 0 min

Share

  • 1

    Breast and cervical cancers are significant public health issues for women in sub-Saharan Africa, particularly in Gabon.

  • 2

    The study analyzed screening outcomes for 1,328 women at CHUAB in Franceville from 2015 to 2021 using CBE and VIA.

  • 3

    Women aged 45–73 years had lower odds of cervical screening positivity compared to those aged 14–25 years.

  • 4

    Non-Gabonese nationality and public sector employment were linked to higher cervical screening positivity.

  • 5

    The study highlights the effectiveness of VIA and CBE in detecting breast and cervical abnormalities in resource-limited settings.

Original Source(s)

Breast and Cervical Cancer Screening in a Semi-Urban African Setting: Evidence from Franceville, Gabon (2015–2021)

  • by MOUSSAVOU-BOUNDZANGA, Pamela , Togola, Moussa , Bivigou-Mboumba, Berthold , Ambounda, Nathalie Ledaga, MOUINGA ONDEME, Augustin , Mfouo-Tynga, Ivan , Mavoungou-Niongo, Anne-Danielle , Nzingou, Aime Roger , Mombo, Landry Erik , Bisseye, Cyrille , Pineau, Pascal

  • April 28, 2026

Related Content

New Mammography Screening Guidance: Clinical Considerations for Risk-Based Care

New guidance from the American College of Physicians (ACP) recommends biennial mammography screening for average-risk women ages 50 to 74.

  • by

  • May 26, 2026

  • 5 min
Mesh-free prepectoral breast reconstruction: a safe and effective alternative

Case Report: response of HER2-positive ductal carcinoma in situ to osimertinib with supporting in vitro evidence